ITI214 free base is primarily investigated for its potential therapeutic applications in the central nervous system. It acts as a phosphodiesterase 1 (PDE1) inhibitor, which plays a role in regulating cyclic nucleotide signaling pathways. This mechanism suggests its utility in addressing neurological and psychiatric disorders. Research has explored its efficacy in conditions such as Parkinson’s disease, where it may help alleviate motor and cognitive symptoms by enhancing dopamine signaling and neuroplasticity. Additionally, it has been studied for its potential in treating schizophrenia, particularly in improving cognitive function and reducing negative symptoms. Its ability to modulate intracellular signaling pathways also makes it a candidate for addressing other neurodegenerative diseases and mood disorders. Ongoing studies aim to further validate its safety and effectiveness in clinical settings.